Urothelial phase CT for assessment of pathologic complete response after neoadjuvant chemotherapy in muscle-invasive bladder cancer

被引:7
|
作者
Choi, Se Jin [1 ,2 ]
Park, Kye Jin [1 ,2 ]
Lee, Goeun [3 ]
Kim, Mi-hyun [1 ,2 ]
Kim, Jeong Kon [1 ,2 ]
机构
[1] Univ Ulsan, Asan Med Ctr, Dept Radiol, Coll Med, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea
[2] Univ Ulsan, Asan Med Ctr, Res Inst Radiol, Coll Med, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea
[3] Univ Ulsan, Asan Med Ctr, Dept Pathol, Coll Med, Seoul 05505, South Korea
基金
新加坡国家研究基金会;
关键词
Bladder cancer; Neoadjuvant chemotherapy; Urothelial phase CT; Pathologic complete response; Clinical complete response; RADICAL CYSTECTOMY; SOLID TUMORS; CARCINOMA; UROGRAPHY; SURVIVAL; MRI;
D O I
10.1016/j.ejrad.2020.108902
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To investigate the diagnostic performance of urothelial phase (UP) CT and identify the appropriate imaging criteria for assessment of pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) in patients with bladder cancer. Method: Seventy-three patients who underwent NAC and subsequent radical or partial cystectomy between January 2017 and July 2019 were retrospectively analyzed. UP CT findings after NAC were divided into five grades as follows: grade 1, no wall thickening or inner-layer enhancement; grade 2, thin inner-layer enhancement without wall thickening; grade 3, inner-layer enhancement with low-attenuation wall thickening; grade 4, wall thickening with enhancement; and grade 5, nodular enhancement or enhanced soft tissue. Two radiologists independently evaluated these grades on the post-chemotherapy CT. The area under the ROC curve (AUC) was used to evaluate diagnostic performance for pCR. Inter-reader agreement was assessed using the kappa coefficient. Results: Twenty-seven patients (37 %) were confirmed with pCR. The AUCs for the assessment of pCR on UP CT were 0.85-0.86 for the two readers. Using absent or thin inner-layer enhancement as features to predict pCR, the sensitivity, specificity, positive predictive value, and negative predictive value were 74.1-81.5 %, 80.4-84.8 %, 71.0-74.1 %, and 84.8-88.1 % for both readers. The inter-reader agreement for grades <= 2 was almost perfect (kappa = 0.83). Conclusions: Absent or thin inner-layer enhancement on UP CT demonstrated high diagnostic performance and high inter-reader agreement for assessment of pCR after neoadjuvant chemotherapy in bladder cancer, and evaluation of this feature could improve the predictive ability of preoperative imaging for assessing pCR.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer
    Bandini, Marco
    Ross, Jeffrey S.
    Raggi, Daniele
    Gallina, Andrea
    Colecchia, Maurizio
    Luciano, Roberta
    Giannatempo, Patrizia
    Fare, Elena
    Pederzoli, Filippo
    Bianchi, Marco
    Colombo, Renzo
    Gandaglia, Giorgio
    Fossati, Nicola
    Marandino, Laura
    Capitanio, Umberto
    Deho', Federico
    Ali, Siraj M.
    Madison, Russell
    Chung, Jon H.
    Salonia, Andrea
    Briganti, Alberto
    Montorsi, Francesco
    Necchi, Andrea
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (01) : 48 - 53
  • [2] Pathologic down-staging and complete pathologic response with gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder
    Psutka, Sarah P.
    Olumi, Aria F.
    Feldman, Adam S.
    Saylor, Philip James
    Kaufman, Donald S.
    Lee, Richard J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [3] Predicting Complete Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
    Miyagi, Hiroko
    Kwenda, Elizabeth
    Ramnaraign, Brian H.
    Chatzkel, Jonathan A.
    Brisbane, Wayne G.
    O'Malley, Padraic
    Crispen, Paul L.
    [J]. CANCERS, 2023, 15 (01)
  • [4] Impact of angiotensin inhibitors on pathologic complete response with neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC).
    Thomas, Jonathan
    Pond, Gregory Russell
    Curran, Catherine
    Freeman, Dory
    Ravi, Praful
    Mossanen, Matthew
    Preston, Mark A.
    Steele, Graeme S.
    Mantia, Charlene
    McGregor, Bradley Alexander
    Jain, Rakesh K.
    Sonpavde, Guru
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [5] Approaches to Clinical Complete Response after Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: Possibilities and Limitations
    Lee, Hye Won
    Kwon, Whi-An
    Nguyen, La Ngoc Thu
    Phan, Do Thanh Truc
    Seo, Ho Kyung
    [J]. CANCERS, 2023, 15 (04)
  • [6] Re: Predicting the Pathologic Complete Response after Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer Editorial Comment
    Chang, Sam S.
    [J]. JOURNAL OF UROLOGY, 2022, 207 (05): : 1154 - 1155
  • [7] Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
    Zargar, Homayoun
    Espiritu, Patrick N.
    Fairey, Adrian S.
    Mertens, Laura S.
    Dinney, Colin P.
    Mir, Maria C.
    Krabbe, Laura-Maria
    Cookson, Michael S.
    Jacobsen, Niels-Erik
    Gandhi, Nilay M.
    Griffin, Joshua
    Montgomery, Jeffrey S.
    Vasdev, Nikhil
    Yu, Evan Y.
    Youssef, David
    Xylinas, Evanguelos
    Campain, Nicholas J.
    Kassouf, Wassim
    Dall'Era, Marc A.
    Seah, Jo-An
    Ercole, Cesar E.
    Horenblas, Simon
    Sridhar, Srikala S.
    McGrath, John S.
    Aning, Jonathan
    Shariat, Shahrokh F.
    Wright, Jonathan L.
    Thorpe, Andrew C.
    Morgan, Todd M.
    Holzbeierlein, Jeff M.
    Bivalacqua, Trinity J.
    North, Scott
    Barocas, Daniel A.
    Lotan, Yair
    Garcia, Jorge A.
    Stephenson, Andrew J.
    Shah, Jay B.
    van Rhijn, Bas W.
    Daneshmand, Siamak
    Spiess, Philippe E.
    Black, Peter C.
    [J]. EUROPEAN UROLOGY, 2015, 67 (02) : 241 - 249
  • [8] Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer
    Vasdev, N.
    Zargar, H.
    Fairey, A.
    Espiritu, P.
    Krabbe, L.
    Mongomery, J.
    Gandhi, N.
    Griffin, J.
    Yu, E.
    Campain, N.
    Xylinas, E.
    Horenblas, S.
    Yousef, D.
    Kassouf, W.
    Shariat, S.
    Aning, J.
    Wright, J.
    Holzbeierlein, J.
    Bivalacqua, T.
    Morgan, T.
    North, S.
    Borcas, D.
    Lotan, Y.
    Shah, J.
    Spiess, P.
    Van Rhijn, B.
    Daneshmand, S.
    Black, P.
    Thorpe, A. C.
    [J]. BJU INTERNATIONAL, 2014, 113 : 25 - 25
  • [9] Sarcopenia and Response to Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer
    Lyon, Timothy D.
    Frank, Igor
    Takahashi, Naoki
    Boorjian, Stephen A.
    Moynagh, Michael R.
    Shah, Paras H.
    Tarrell, Robert F.
    Cheville, John C.
    Viers, Boyd R.
    Tollefson, Matthew K.
    [J]. CLINICAL GENITOURINARY CANCER, 2019, 17 (03) : 216 - +
  • [10] Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma
    Pokuri, Venkata K.
    Syed, Johar R.
    Yang, Zhengyu
    Field, Erinn P.
    Cyriac, Susanna
    Pili, Roberto
    Levine, Ellis Glenn
    Azabdaftari, Gissou
    Trump, Donald L.
    Guru, Khurshid
    George, Saby
    [J]. CLINICAL GENITOURINARY CANCER, 2016, 14 (01) : E59 - E65